Genmab, AbbVie clarify primary endpoints in Phase 3 EPCORE DLBCL-1 trial
ABBV•Clarification on primary endpoints
Genmab issued a clarification correcting how primary endpoints were described for the Phase 3 EPCORE DLBCL-1 epcoritamab trial.
In the U.S., overall survival was the sole primary endpoint; the study missed it, with no statistically significant overall survival improvement.
Region-specific endpoints and next steps
The trial uses region-specific primary endpoints, creating a mismatch with earlier topline messaging; additional results are slated for journal submission.
